News and Announcements
Proteomics International Receives R&D Tax Incentive
- Published November 18, 2015 12:06PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th November 2015, ASX Announcement
Life sciences company Proteomics International Laboratories Ltd (ASX: PIQ) (the Company, PILL) is pleased to announce it has received an Australian Government R&D Tax Incentive payment of $309,010 for the year ending 30 June 2015.
The Company received the R&D Tax Incentive after spending in excess of $700,000 on R&D activities within its world leading proteomics-focused business in the 2014-15 financial year.
The funds from the R&D Tax Incentive will complement PILL’s existing cash reserves and be used to continue to advance the application and commercialisation of the Company’s products and services derived from its proteomics-based technology platform.
Proteomics is the industrial scale study of the structure and function of proteins and PILL is recognised as a global leader in its field.
To read the full announcement, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
